You just read:

Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

News provided by

Theravance Biopharma, Inc.

Sep 09, 2019, 07:05 ET